Back to Browse Journals » Clinical Interventions in Aging » Volume 3 » Issue 4

Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene

Authors Victor G Vogel

Published 5 December 2008 Volume 2008:3(4) Pages 601—609


Review by Single-blind

Peer reviewer comments 2

Victor G Vogel

The University of Pittsburgh Cancer Institute, Magee-Womens Hospital, Pittsburgh, PA, USA

Abstract: Raloxifene hydrochloride is a selective estrogen receptor modulator (SERM) that has antiestrogenic effects on breast and endometrial tissue and estrogenic effects on bone, lipid metabolism, and blood clotting. Raloxifene significantly improves serum lipids and serum markers of cardiovascular disease risk, but it has no significant effect on the risk of primary coronary events. A meta-analysis of randomized, double-blind, placebo-controlled trials of raloxifene for osteoporosis showed the odds of fracture risk were 0.60 (95% confidence interval [CI] = 0.49–0.74) for raloxifene 60 mg/day compared with placebo. During 8 years of follow-up in an osteoporosis trial, the raloxifene group had a 76% reduction in the incidence of invasive ER-positive breast cancer compared with the placebo group. In the STAR trial, the incidence of invasive breast cancer was 4.30 per 1000 women-years with raloxifene and 4.41 per 1000 with tamoxifen; RR = 1.02; 95% CI, 0.82–1.28. The effect of raloxifene on invasive breast cancer was, therefore, equivalent to that of tamoxifen with more favorable rates of adverse effects including uterine malignancy and clotting events. Millions of postmenopausal women could derive net benefit from raloxifene through reduced rates of fracture and invasive breast cancer.

Keywords: raloxifene, osteoporosis, breast cancer risk reduction

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other article by this author:

Readers of this article also read:

Unexpected and permanent central visual loss after removal of intraocular silicone oil

Toso A, Cappello E, Morselli S

Clinical Ophthalmology 2014, 8:1831-1836

Published Date: 11 September 2014

Targeted dual-color silica nanoparticles provide univocal identification of micrometastases in preclinical models of colorectal cancer

Soster M, Juris R, Bonacchi S, Genovese D, Montalti M, Rampazzo E, Zaccheroni N, Garagnani P, Bussolino F, Prodi L, Marchiò S

International Journal of Nanomedicine 2012, 7:4797-4807

Published Date: 5 September 2012

Berberine hydrochloride: anticancer activity and nanoparticulate delivery system

Tan W, Li YB, Chen MW, Wang YT

International Journal of Nanomedicine 2011, 6:1773-1777

Published Date: 24 August 2011

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes

Jacqueline S Garcia, Nitin Jain, Lucy A Godley

OncoTargets and Therapy 2010, 3:1-13

Published Date: 25 February 2010

Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck

Francesco Perri, Francesco Longo, Franco Ionna, et al

OncoTargets and Therapy 2009, 2:243-250

Published Date: 31 August 2009

Clinical challenges in the management of osteoporosis

Sheryl F Vondracek, Paul Minne, Michael T McDermott

Clinical Interventions in Aging 2008, 3:315-329

Published Date: 6 June 2008

The prognostic value of injury severity, location of event, and age at injury in pediatric traumatic head injuries

Jonas G Halldorsson, Kjell M Flekkoy, Gudmundur B Arnkelsson, Kristinn Tomasson, Kristinn R Gudmundsson, Eirikur Orn Arnarson

Neuropsychiatric Disease and Treatment 2008, 4:405-412

Published Date: 11 April 2008

The biopsychosocial effects of restless legs syndrome (RLS)

Philip M Becker

Neuropsychiatric Disease and Treatment 2006, 2:505-512

Published Date: 15 December 2006

Frontotemporal dementia: remembering images from the past

Paul Mackin, R Hamish McAllister-Williams

Neuropsychiatric Disease and Treatment 2005, 1:281-283

Published Date: 15 October 2005